Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01085630 : Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Histologically confirmed malignant pleural mesothelioma meeting 1 of the following
cell types:

- Epithelial

- Sarcomatoid

- Mixed type

- Histologically documented malignant pleural mesothelioma, epithelial,
sarcomatoid or mixed type, not amenable to surgical resection

- Prior treatment

- Currently receiving first-line treatment with pemetrexed + platinum; patients are to
be registered to Cancer and Leukemia Group B (CALGB) 30901 no later than the last day
of cycle 4 of first line therapy

- Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) are
acceptable; prior intrapleural cytotoxic chemotherapy will not be considered systemic
chemotherapy

- Prior surgical treatment is allowed

- Prior radiation therapy is allowed

- Non-pregnant and non-nursing; women of child bearing potential and men must
agree to use an appropriate method of birth control throughout their
participation in this study; appropriate methods of birth control include
abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant),
or double barrier methods (diaphragm plus condom)

- RANDOMIZATION ELIGIBILITY CRITERIA

- Patients with complete response, partial response, or stable disease following
4, 5 or 6 cycles of first-line chemotherapy with pemetrexed AND either cisplatin
or carboplatin; a maximum of 6 cycles of chemotherapy may have been given

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Granulocytes >= 1,500/ul

- Platelet count >= 100,000/ul

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT]) =< 2 x ULN

- Calculated creatinine clearance >= 45 ml/min

- Disease not amenable to surgery

- Must be enrolled on imaging protocol CALGB-580903

- Complete response, partial response, or stable disease after completion of 4 courses
of first-line chemotherapy comprising pemetrexed disodium AND cisplatin or
carboplatin

- Study therapy will begin within 9 weeks following day 1 of cycle 4 of first-line
treatment

- No clinically significant pleural or peritoneal effusions that cannot be adequately
managed by drainage before or during pemetrexed disodium

PATIENT CHARACTERISTICS:

- ECOG performance status of 0-1

- Life expectancy ? 12 weeks

- Granulocytes ? 1,500/?L

- Platelet count ? 100,000/?L

- Total bilirubin ? 1.5 times upper limit of normal (ULN)

- AST ? 2 times ULN

- Creatinine clearance ? 45 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No psychiatric illness that would prevent the patient from giving informed consent

- No second malignancy except non-melanoma skin cancer or carcinoma in situ of the
cervix unless curatively treated with no evidence of active disease for ? 5 years

- No medical conditions that, in the opinion of the treating physician, would make
study treatment unreasonably hazardous for the patient including, but not limited to,
the following:

- Ongoing or active infection such as HIV positivity

- Inability to take oral medications

- Psychiatric illness/social situations that would limit compliance with study
requirements

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed

- Prior intrapleural cytotoxic chemotherapy not considered systemic chemotherapy

- Prior surgery allowed

- Prior radiotherapy allowed

- No concurrent palliative radiotherapy

- No concurrent hormones or other chemotherapeutic agents except for the following:

- Steroids for adrenal failure

- Hormones for nondisease-related conditions (e.g., insulin for diabetes)

- Intermittent use of dexamethasone as an antiemetic or premedication for
pemetrexed disodium
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01085630      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740